Last edition
News about "Trastuzumab Rezetecan "
Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer
Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.
Trastuzumab Rezetecan | 04/07/2026 | By News Bureau
Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer
Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.
Trastuzumab Rezetecan | 02/07/2026 | By News Bureau
Glenmark Secures USD 1.0 Billion Licensing Deal for Next-Gen Cancer Drug with Chinese Partner
Under the terms of the deal, Glenmark will make an upfront payment of USD 18 million and may pay up to USD 1.093 billion in regulatory and commercial milestone payments, in addition to royalties tied to future sales.
Trastuzumab Rezetecan | 25/09/2025 | By Darshana | 272
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy